射血分数保留的心力衰竭的药物治疗研究进展  

Research Progress of Drug Therapy for Heart Failure with Preserved Ejection Fraction

作　　者：刘春秋 熊双 刘剑刚[2] 董国菊[1,2] LIU Chunqiu;XIONG Shuang;LIU Jiangang;DONG Guoju(Department of Cardiovascular Medicine,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;National Center for Clinical Cardiovascular Diseases of Traditional Chinese Medicine,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;Graduate School of China Academy of Chinese Medical Sciences,Beijing 100700,China)

机构地区：[1]中国中医科学院西苑医院心血管科,北京100091 [2]中国中医科学院西苑医院国家中医临床心血管病医学研究中心,北京100091 [3]中国中医科学院研究生院,北京100700

出　　处：《医学综述》2022年第3期517-521,共5页Medical Recapitulate

基　　金：国家自然科学基金(82074423);中国中医科学院科技创新工程课题(CI2021A00903)。

摘　　要：由于射血分数保留的心力衰竭(HFpEF)的机制和表型的复杂性,HFpEF的治疗较困难,既往应用于射血分数降低的心力衰竭的治疗药物大多对HFpEF疗效不佳。目前的治疗大多通过药物、非药物治疗的方式,并以改善症状、降低住院率、延长寿命为主要目的,其中钠-葡萄糖协同转运蛋白2抑制剂、血管紧张素受体脑啡肽酶抑制剂和他汀类药物表现突出,可能成为HFpEF治疗的突破点。近期HFpEF研究方向则多以能够降低HFpEF病死率、改善患者预后的新药研制为主。Due to the complexity of the mechanism and phenotype of heart failure with preserved ejection fraction(HFpEF),it is difficult to treat HFpEF.Most of the drugs used in the past for heart failure with reduced ejection fraction have poor efficacy to HFpEF.At present,most of the treatment is through drug and non-drug treatment,and the main purpose is to improve symptoms,reduce hospitalization rate and prolong life.Among them,sodium-glucose cotransporter 2 inhibitor,angiotensin receptor enkephalinase inhibitor and statins are outstanding,which may become a breakthrough point in the treatment of HFpEF.The latest research directions mainly focus on the development of new drugs to reduce the fatality rate of HFpEF and improve the prognosis of the patients.

关 键 词：射血分数保留的心力衰竭 血管紧张素受体脑啡肽酶抑制剂 他汀类药物 钠-葡萄糖协同转运蛋白2抑制剂 

分 类 号：R541.6[医药卫生—心血管疾病]